While it was beyond the scope of this work to characterize the precise mechanism and cross-talk among the individual immune cell types, a critical dependence on the cytotoxic T cell response for the therapeutic outcome of VSV-NDV therapy is strongly implicated by the complete ablation of tumor responses in the context of CD8+ T cell depletion. The gene discussed is CD8A; the disease is neoplasm.